Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 12/20 | 0.41 |
| ▸ | JAK2 | O60674 | 7/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668192 | 0.88 | JAK1 (0.47) | JAK1JAK2JAK3 | |
| SCHEMBL23668175 | 0.86 | JAK1 (0.43) | JAK1JAK2JAK3CDK2CCNE1 | |
| SCHEMBL30810135 | 0.79 | BRD4 (0.44) | FLT3DYRK1BBRD4IKBKBCHUK | |
| SCHEMBL23668186 | 0.79 | BRD4 (0.44) | FLT3DYRK1BBRD4IKBKBCHUK | |
| SCHEMBL24065964 | 0.73 | JAK1 (0.60) | JAK1JAK2TYK2JAK3CDK2 | |
| SCHEMBL30810116 | 0.71 | JAK1 (0.44) | JAK1JAK2JAK3CDK2 | |
| SCHEMBL23668182 | 0.69 | ABL1 (0.39) | BRD4 | |
| SCHEMBL23668193 | 0.68 | JAK1 (0.43) | JAK1JAK2TYK2 | |
| SCHEMBL23668176 | 0.68 | L3MBTL1 (0.42) | BRD4 | |
| SCHEMBL30810137 | 0.68 | L3MBTL1 (0.42) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3854793-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | JAK1, JAK2, JAK3 | FLT3 48/4885JAK1 1/4885JAK2 2/4885 |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | JAK1, JAK2, JAK3 | FLT3 48/4885JAK1 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.